Coya Therapeutics, Inc. (NASDAQ:COYA) Insider Fred Grossman Acquires 2,710 Shares

Coya Therapeutics, Inc. (NASDAQ:COYA) insider Fred Grossman bought 2,710 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were bought at an average price of $7.37 per share, with a total value of $19,972.70. Following the purchase, the insider now owns 2,710 shares in the company, valued at $19,972.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Coya Therapeutics Price Performance

Shares of COYA opened at $7.25 on Wednesday. Coya Therapeutics, Inc. has a twelve month low of $4.75 and a twelve month high of $10.69. The company’s fifty day simple moving average is $7.07 and its 200-day simple moving average is $7.01.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.15. On average, research analysts expect that Coya Therapeutics, Inc. will post -1.27 earnings per share for the current year.

Hedge Funds Weigh In On Coya Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Gilbert & Cook Inc. purchased a new position in Coya Therapeutics in the second quarter worth $61,000. Renaissance Technologies LLC acquired a new position in shares of Coya Therapeutics in the 2nd quarter valued at about $101,000. GHP Investment Advisors Inc. purchased a new stake in shares of Coya Therapeutics during the 3rd quarter valued at about $169,000. Finally, Vanguard Group Inc. increased its holdings in Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after purchasing an additional 750,338 shares during the last quarter. 39.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on COYA. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a report on Monday. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Thursday, November 7th.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.